ReviewCellular oncology (Dordrecht, Netherlands)2023
The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis.
Review in Cellular oncology (Dordrecht, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- The molecular mechanisms of platelets in tumor invasion and metastasis: a controversial role.Cancer biology & therapy · 2026Review
- Platelet FcɣRIIa: a novel biomarker of risk for thromboembolism and death in cancer.Journal of thrombosis and thrombolysis · 2026Observational
- Platelet-to-Albumin Ratio and Clinical Outcomes in IDH-Wildtype Grade 4 Diffuse Glioma.Journal of clinical medicine · 2026Article
- Establishment and validation of a diagnostic model for evaluating synchronous liver metastasis in pancreatic cancer using comprehensive blood biochemical indicators.Oncology letters · 2026Article
- Review
- Targeting platelet-tumor cell interactions: a novel approach to cancer therapy.Medical oncology (Northwood, London, England) · 2025Review
- Inflammation-targeted nanomedicine prevents tumor metastasis following photodynamic therapy by reversing epithelial-mesenchymal transition and ROS-mediated immunosuppression.Journal of nanobiotechnology · 2025Article
- Utilization of TEP miRNAs in tumor proliferation, diagnostic evaluation, therapeutic intervention, and prognostic assessment.Molecular biology reports · 2025Review
- The potential clinical value of platelet aggregation in colorectal tumor progression.Discover oncology · 2024Article
- Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication.Journal of nanobiotechnology · 2024Review
- Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment.Biomarker research · 2024Review
- Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens.Journal of translational medicine · 2024Article
- Thromboelastography (TEG) parameters as potential predictors of malignancy and tumor progression in colorectal cancer.World journal of surgical oncology · 2023Article
- Predicting the prognosis of operable gastric cancer patients by dynamic changes in platelets before and after surgery: a retrospective cohort study.Journal of cancer research and clinical oncology · 2023Article
- Radiomics features from whole thyroid gland tissue for prediction of cervical lymph node metastasis in the patients with papillary thyroid carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Antithrombotic strategy in cancer patients comorbid with acute coronary syndrome and atrial fibrillation.Frontiers in cardiovascular medicine · 2023Review
- Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundIn addition to their pivotal roles in coagulation and thrombosis, platelets are crucial in tumor progression, with plenty of clinical and experimental data demonstrating that the interplay of platelets and tumor cells is essential for hematogenous tumor metastasis. After detach from primary sites, tumor cells intravasate into the blood circulation becoming circulating tumor cells and induce platelet activation, aggregation and encasement around tumor cells to form micro tumor thrombi, which create a permissive tumor microenvironment for metastasis. Platelets in micro tumor thrombi protect tumor cells from immune surveillance and anoikis (detachment-triggered apoptosis) through various pathways, which are significant for tumor cell survival in the bloodstream. Moreover, platelets can facilitate tumor metastasis by expediting epithelial-mesenchymal transition (EMT), adhesion to the endothelium, angiogenesis, tumor proliferation processes and platelet-derived microvesicle (PMV) formation.
conclusionsHere, we provide a synopsis of the current understanding of the formation of micro tumor thrombi and the role of micro tumor thrombi in tumor hematogenous metastasis based on the tumor-platelet interplay. We also highlight potential therapeutic strategies targeting platelets for tumor treatment, including cancer-associated platelet-targeted nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.